Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3006441852, Phoenix, Arizona, United States. Part of Abraxis BioScience's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 10
Official action indicated: 1
Last inspection ended: Oct 6, 2023
Warning letters: 2
Inspections by Fiscal Year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
21 CFR 211.170(b). Annual visual exams of drug products Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
21 CFR 211.42(c)(10)(vi). Equipment to control conditions Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
21 CFR 211.68(b). input/output verification Input to and output from the computer, related systems of formulas and records or data are not checked for accuracy.
21 CFR 211.192. Written record of investigation incomplete Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
21 CFR 211.194(a)(8). Second person sign off Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness and compliance with established standards.
Voluntary Action Indicated (VAI)
Apr 6, 2022
Drugs · Drug Quality Assurance
2 cited references
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
21 CFR 211.113(b). Procedures for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Official Action Indicated (OAI)
Feb 19, 2020
Drugs · Drug Quality Assurance
4 cited references
21 CFR 211.192. Written record of investigation incomplete Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
21 CFR 211.68(b). Computer control of master formula records Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
21 CFR 211.100(b). SOPs not followed / documented Written production and process control procedures are not followed in the execution of production and process control functions.
21 CFR 211.100(b). Procedure Deviations Recorded and Justified Deviations from written production and process control procedures are not recorded.
Voluntary Action Indicated (VAI)
Aug 17, 2018
Drugs · Drug Quality Assurance
2 cited references
21 CFR 211.63. Equipment Design, Size and Location Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
21 CFR 211.160(a). Following/documenting laboratory controls Established laboratory control mechanisms are not followed and documented at the time of performance.
Voluntary Action Indicated (VAI)
Jun 24, 2016
Drugs · Drug Quality Assurance
3 cited references
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
21 CFR 211.165(a). Testing and release for distribution Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
21 CFR 211.68(b). input/output verification Input to and output from the computer, related systems of formulas and records or data are not checked for accuracy. Electronic records are used, but they do not meet system access limitation requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.
Voluntary Action Indicated (VAI)
Aug 8, 2014
Drugs · Drug Quality Assurance
2 cited references
21 CFR 211.160(b)(3). Drug products-sampling procedures/specifications Laboratory controls do not include a determination of conformance to written descriptions of sampling procedures for drug products.
21 CFR 211.113(b). Procedures for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Voluntary Action Indicated (VAI)
Sep 16, 2013
Drugs · Drug Quality Assurance
None posted
No Action Indicated (NAI)
Jun 8, 2012
Drugs · Drug Quality Assurance
None posted
No Action Indicated (NAI)
Sep 2, 2010
Drugs · Drug Quality Assurance
None posted
No Action Indicated (NAI)
Sep 4, 2009
Drugs · Drug Quality Assurance
None posted
No Action Indicated (NAI)
Warning Letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm.FDA Data Dashboard, warning letters and enforcement reports